Both primary as well as multiple secondary endpoints were met in the trial.
News & Analysis: Akcea Therapeutics, Inc.
The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.
Investors are overly focused on one issue with this stock while the company is making progress on many fronts.
AKCA earnings call for the period ending September 30, 2019.
Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
A licensing deal gives investors confidence in a turnaround.
Find out which of these companies investors are the most nervous about.
AKCA earnings call for the period ending June 30, 2019.
AKCA earnings call for the period ending March 31, 2019.
AKCA earnings call for the period ending December 31, 2018.